Akseli Hemminki

Akseli Hemminki is a prominent figure in the field of oncology with extensive experience in both academic and industry roles. He currently holds multiple positions:

Professional Roles

• Professor of Oncology at the University of Helsinki1
• CEO of TILT Biotherapeutics, a company focused on cancer immunotherapy23
• Previously served as Head of Department at Helsinki University Hospital Comprehensive Cancer Center1

Academic Background

Hemminki has a strong educational foundation, having studied at:

• University of Helsinki
• Helsinki University Central Hospital
• University of Alabama at Birmingham1

Research and Expertise

Akseli Hemminki is a renowned researcher in the field of oncology:

• He has published hundreds of papers in the field of oncology4
• Has treated almost 300 patients with 10 different oncolytic viruses4
• Founded Oncos Therapeutics, where he served as a scientific founder and board member1

Current Focus

At TILT Biotherapeutics, Hemminki is leading efforts to advance cancer immunotherapy:

• The company has recently raised significant funding ($23,611,000) to support their research and development4
• They are working on innovative approaches to cancer treatment, likely involving oncolytic viruses based on Hemminki's expertise

Akseli Hemminki's career demonstrates a strong commitment to advancing cancer treatment through both academic research and practical applications in the biotech industry.